Longeveron (LGVN) Notes Payables (2021 - 2023)
Longeveron (LGVN) recorded quarterly Notes Payables of $457000.0 in Q1 2023, down 73.9% quarter-over-quarter from $1.8 million in Q4 2022.
Longeveron (LGVN) Notes Payables (2021 - 2023) Analysis & Trends
Longeveron's Notes Payables history runs 3 years deep, the most recent figure standing at $457000.0 for Q1 2023.
- In Q1 2023, Notes Payables changed N/A year-over-year to $457000.0; the TTM figure through Mar 2023 stood at $457000.0 (changed N/A YoY), while the FY2022 annual figure was $1.8 million, up 171.47% from the prior year.
- Notes Payables was $457000.0 for Q1 2023 at Longeveron, down from $1.8 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $1.8 million in Q4 2022 to a low of $457000.0 in Q1 2023.
- Historically, Notes Payables has averaged $951000.0 across 3 years, with a median of $645000.0 in 2021.
- Biggest YoY gain for Notes Payables was 171.47% in 2022; the steepest drop was 171.47% in 2022.
- A 3-year view of Notes Payables shows it stood at $645000.0 in 2021, then jumped by 171.47% to $1.8 million in 2022, then slumped by 73.9% to $457000.0 in 2023.
- The last three Notes Payables figures came in at $457000.0 (Q1 2023), $1.8 million (Q4 2022), and $645000.0 (Q4 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 457,000.00 |
| Dec 31, 2022 | 1.75 Mn |
| Dec 31, 2021 | 645,000.00 |